C4 Therapeutics, Inc. (CCCC) Profit Margins
Over the twelve months to 2026-06-30, C4 Therapeutics, Inc. (CCCC) had operating margin -319.0%, net margin -289.4%, free cash flow margin -243.7%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CCCCC4 Therapeutics, Inc.Follow CCCC — free
—
Price chart with a free account
- Market cap
- 376.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Gross margin | — | — | 93.2% | 70.1% | — | |
| Operating margin | -416.6% | -669.8% | -336.1% | -320.5% | -319.0% | |
| Net margin | -412.2% | -638.3% | -296.0% | -292.1% | -289.4% | |
| FCF margin | -358.4% | -523.0% | -183.6% | -276.2% | -243.7% |
USD millions · SEC XBRL
C4 Therapeutics, Inc. — questions
- What is C4 Therapeutics, Inc.'s operating margin?
- -319.0% over the twelve months to 2026-06-30.
- What is C4 Therapeutics, Inc.'s net profit margin?
- -289.4% over the twelve months to 2026-06-30.
Every figure on this page comes from C4 Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.